Shares of gene editing therapy companies surged by double digits recently, driven by two key catalysts. The first was the European Society of Gene and Cell Therapy’s 33rd ESGCT Annual Congress, which concluded with numerous positive data presentations from developers of new editing-based therapies. The second catalyst was the FDA’s draft guidance issued on October 27, aimed at assisting sponsors in developing personalized gene therapies for rare genetic diseases. This guidance introduces the concept of the Individualized Feature Space (IFS), allowing for variations in genome-edited products without necessitating additional clinical trials, thus streamlining the Biologics License Application (BLA) process.
Investors reacted positively to these developments, with shares of several gene editing companies rising significantly. For instance, Prime Medicine’s shares jumped 29%, while Beam Therapeutics saw a 13% increase. The FDA’s framework may support accelerated approval paths for these companies, potentially enhancing their market positions as they approach critical clinical milestones.
Source: genengnews.com · Image: Naitō Museum of Pharmaceutical Science and Industry 20220505 12 by 先従隗始, CC0, via Wikimedia Commons
Get started today with Solo access →
